Re: Treatment of human epidermal growth factor receptor 2 overexpressing breast cancer xenografts with multiagent human epidermal growth factor receptor targeted therapy

Comment

Gianluigi Ferretti et al. J Natl Cancer Inst. 2007.

. 2007 Nov 7;99(21):1644; author reply 1644-6.

doi: 10.1093/jnci/djm175. Epub 2007 Oct 30.

No abstract available

Comment on

Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial.
Powles TJ, Ashley S, Tidy A, Smith IE, Dowsett M. Powles TJ, et al. J Natl Cancer Inst. 2007 Feb 21;99(4):283-90. doi: 10.1093/jnci/djk050. J Natl Cancer Inst. 2007. PMID: 17312305 Clinical Trial.
Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy.
Arpino G, Gutierrez C, Weiss H, Rimawi M, Massarweh S, Bharwani L, De Placido S, Osborne CK, Schiff R. Arpino G, et al. J Natl Cancer Inst. 2007 May 2;99(9):694-705. doi: 10.1093/jnci/djk151. J Natl Cancer Inst. 2007. PMID: 17470737
Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy.
Veronesi U, Maisonneuve P, Rotmensz N, Bonanni B, Boyle P, Viale G, Costa A, Sacchini V, Travaglini R, D'Aiuto G, Oliviero P, Lovison F, Gucciardo G, del Turco MR, Muraca MG, Pizzichetta MA, Conforti S, Decensi A; Italian Tamoxifen Study Group. Veronesi U, et al. J Natl Cancer Inst. 2007 May 2;99(9):727-37. doi: 10.1093/jnci/djk154. J Natl Cancer Inst. 2007. PMID: 17470740 Clinical Trial.